Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 19;57(7):732.
doi: 10.3390/medicina57070732.

Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project

Karolina Polewska  1 , Piotr Tylicki  1 , Bogdan Biedunkiewicz  1 , Angelika Rucińska  2 , Aleksandra Szydłowska  2 , Alicja Kubanek  2 , Iwona Rosenberg  3 , Sylwia Rodak  3 , Waldemar Ślizień  3 , Marcin Renke  2 , Alicja Dębska-Ślizień  1 , Leszek Tylicki  1
Affiliations

Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project

Karolina Polewska et al. Medicina (Kaunas). .

Abstract

Background and Objectives: The Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine has demonstrated excellent efficacy and safety in phase 3 trials. However, no dialyzed patients were included, and therefore safety data for this patient group is lacking. The aim of the study was to assess the safety and tolerances of vaccinations with BNT162b2 performed in chronically dialyzed patients. Materials and Methods: We performed a prospective cohort study including a group of 190 dialyzed patients (65% male) at median age 68.0 (55-74) years. 169 (89.0%) patients were treated with hemodialysis and 21 (11.0%) with peritoneal dialysis. The control group consisted of 160 people (61% male) without chronic kidney disease at median age 63 (range 53-77) years. Both groups were vaccinated with BNT162b2 with a 21-day interval between the first and the second dose. Solicited local and systemic reactogenicity, unsolicited adverse events and antipyretic and pain medication use were assessed with a standardized questionnaire. The toxicity grading scales were derived from the FDA Center for Biologics Evaluation and Research guidelines. Results: 59.8% (dose 1), 61.4% (dose 2) and 15.9% (dose 1), 29.4% (dose 2) dialyzed patients reported at least one local and one systemic reaction respectively within seven days after the vaccination. Many local and systemic solicited reactions were observed less frequently in dialyzed patients than in the age and sex matched control group and much less frequently than reported in the pivotal study. They were mostly mild to moderate, short-lived, and more frequently reported in younger individuals and women. No related unsolicited adverse events were observed. Conclusions: We have shown here that BNT162b2, an mRNA vaccine from Pfizer-BioNTech against SARS-COV-2 is safe and well-tolerated by dialyzed patients. The results can be useful for the nephrological community to resolve patients' doubts and reduce their vaccine hesitancy.

Keywords: COVID-19; SARS-CoV-2; dialysis; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Local and systemic solicited adverse events after 1st and 2nd vaccine dose.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Francis A., Baigent C., Ikizler T.A., Cockwell P., Jha V. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: A call to action. Kidney Int. 2021;99:791–793. doi: 10.1016/j.kint.2021.02.003. - DOI - PMC - PubMed
    1. Puchalska-Reglińska E., Dębska-Slizień A., Biedunkiewicz B., Tylicki P., Polewska K., Rutkowski B., Gellert R., Tylicki L. Extremely high mortality in COVID-19 hemodialyzed patients before the anti-SARS-CoV-2 vaccination era. Large database from the North of Poland. Pol. Arch. Intern. Med. 2021 doi: 10.20452/pamw.16028. - DOI - PubMed
    1. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines. 2021;9:160. doi: 10.3390/vaccines9020160. - DOI - PMC - PubMed
    1. Garcia P., Montez-Rath M.E., Moore H., Flotte J., Fults C., Block M.S., Han J., Dittrich M., Parsonnet J., Chertow G.M., et al. SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey. J. Am. Soc. Nephrol. 2021 doi: 10.1681/ASN.2021010104. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Perez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed